BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

...not include $25 million investment in early 2006 that gave Gilead the option to acquire Corus Pharma Inc....
...Lead product gained Lead status at time of deal Disease area Year Value Current status Corus Pharma Inc....
BioCentury | Dec 24, 2014
Financial News

CardioDx withdraws IPO

...the offering. Jefferies; Piper Jaffray; and William Blair were to be underwriters. CardioDx markets its Corus...
BioCentury | Jul 14, 2014
Clinical News

Corus CAD regulatory update

...health care benefits companies Aetna Inc. and Aetna’s Coventry Health Care Inc. will cover CardioDx’s Corus...
...samples are processed in the company’s CLIA-certified laboratory. CardioDx Inc ., Palo Alto, Calif. Product: Corus...
BioCentury | Apr 30, 2014
Financial News

CardioDx revives IPO plans

...of shares. Jefferies; Piper Jaffray; and William Blair are listed as underwriters. CardioDx markets its Corus...
BioCentury | Nov 16, 2013
Financial News

Xencor, CardioDx postpone IPOs

...an option to license the compound (see BioCentury, July 12, 2010) . CardioDx markets its Corus...
BioCentury | Nov 5, 2013
Financial News

Xencor, CardioDx set IPO ranges

...an option to license the compound (see BioCentury, July 12, 2010) . CardioDx markets its Corus...
BioCentury | Oct 12, 2013
Top Story

Four more biotechs join IPO queue

...IPO. BofA Merrill Lynch; Jefferies; Piper Jaffray; and William Blair are underwriters. CardioDx markets its Corus...
BioCentury | Nov 5, 2012
Clinical News

Corus CAD regulatory update

...CardioDx said data from a health economics study showed its Corus CAD gene expression test as...
...symptoms suggestive of coronary artery disease (CAD). Specifically, CardioDx said the study found that using Corus...
...life year (QALY) gained "in a patient cohort closely resembling the commercial intended population for Corus...
BioCentury | Sep 3, 2012
Finance

Reimbursement money

...week's $58 million series F round to nail down private payer reimbursement for the company's Corus...
...far, private payers have reimbursed 15-20% of the more than 30,000 tests administered, he said. Corus...
BioCentury | Aug 28, 2012
Financial News

CardioDx raises $58M in F round

...the round. Earlier this month, Medicare administrator Palmetto GBA said it will reimburse for CardioDx's Corus...
Items per page:
1 - 10 of 105
BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

...not include $25 million investment in early 2006 that gave Gilead the option to acquire Corus Pharma Inc....
...Lead product gained Lead status at time of deal Disease area Year Value Current status Corus Pharma Inc....
BioCentury | Dec 24, 2014
Financial News

CardioDx withdraws IPO

...the offering. Jefferies; Piper Jaffray; and William Blair were to be underwriters. CardioDx markets its Corus...
BioCentury | Jul 14, 2014
Clinical News

Corus CAD regulatory update

...health care benefits companies Aetna Inc. and Aetna’s Coventry Health Care Inc. will cover CardioDx’s Corus...
...samples are processed in the company’s CLIA-certified laboratory. CardioDx Inc ., Palo Alto, Calif. Product: Corus...
BioCentury | Apr 30, 2014
Financial News

CardioDx revives IPO plans

...of shares. Jefferies; Piper Jaffray; and William Blair are listed as underwriters. CardioDx markets its Corus...
BioCentury | Nov 16, 2013
Financial News

Xencor, CardioDx postpone IPOs

...an option to license the compound (see BioCentury, July 12, 2010) . CardioDx markets its Corus...
BioCentury | Nov 5, 2013
Financial News

Xencor, CardioDx set IPO ranges

...an option to license the compound (see BioCentury, July 12, 2010) . CardioDx markets its Corus...
BioCentury | Oct 12, 2013
Top Story

Four more biotechs join IPO queue

...IPO. BofA Merrill Lynch; Jefferies; Piper Jaffray; and William Blair are underwriters. CardioDx markets its Corus...
BioCentury | Nov 5, 2012
Clinical News

Corus CAD regulatory update

...CardioDx said data from a health economics study showed its Corus CAD gene expression test as...
...symptoms suggestive of coronary artery disease (CAD). Specifically, CardioDx said the study found that using Corus...
...life year (QALY) gained "in a patient cohort closely resembling the commercial intended population for Corus...
BioCentury | Sep 3, 2012
Finance

Reimbursement money

...week's $58 million series F round to nail down private payer reimbursement for the company's Corus...
...far, private payers have reimbursed 15-20% of the more than 30,000 tests administered, he said. Corus...
BioCentury | Aug 28, 2012
Financial News

CardioDx raises $58M in F round

...the round. Earlier this month, Medicare administrator Palmetto GBA said it will reimburse for CardioDx's Corus...
Items per page:
1 - 10 of 105